| Website | atossagenetics.com |
| Blog | atossagenetics.co... |
| @AtossaGenetics | |
| Category | BioTech |
| Phone | 206.325.6086 |
| Employees | |
| Founded | 2009 |
| TOTAL | $6.6M |
| FUNDING TOTAL | $6.6M |
| Venture Round, 6/11 | $6.6M |
Atossa Genetics is a health care company focused on the development and marketing of novel cellular and molecular diagnostic risk assessment products for breast cancer.
Using our patented, FDA-approved Mammary Aspirate Specimen Cytology Test (MASCT) System, a nurse or physician’s assistant, can painlessly collect a sample of Nipple Aspirate Fluid (NAF) in about 10 minutes. The NAF sample contains cells (cytology) and molecular diagnostic biomarkers that are useful in finding cancers and pre-cancerous changes, especially Atypical Ductal Hyperplasia (ADH), which confers a higher risk of developing breast cancer.
